Current and future roles of targeted therapy and immunotherapy in advanced melanoma

Journal of Managed Care Pharmacy

Volumn 20, Issue 4, 2014, Pages 346-356

  Olszanski, Anthony J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEVER; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; KERATOACANTHOMA; LIVER TOXICITY; LONG TERM CARE; LONG TERM SURVIVAL; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NATURAL KILLER CELL; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETREATMENT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VISUAL IMPAIRMENT; CANCER STAGING; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84897014639     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.4.346     Document Type: Article

References (80)

1. American Cancer Society. Cancer facts & figures 2014. Available at: http:// www.cancer.org/acs/groups/content/atresearch/documents/webcontent/acspc-042151.pdf. Accessed March 7, 2014.
2. Bleyer A, O'Leary M, Barr R, Ries LAG, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival:1975-2000. Bethesda, MD: National Cancer Institute; 2006.
3. Howlader N, Noone AM, Yu M, Cronin KA. Use of imputed populationbased cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol. 2012;176(4):347-56.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
5. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-34.
6. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16(1):5-24.
7. Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncol. 2009;5(4):543-57.
8. HYDREA (hydroxyurea) prescribing information. Bristol-Myers Squibb Co. Revised July 2011. Available at: http://packageinserts.bms.com/pi/ pi_hydrea.pdf. Accessed January 29, 2014.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
11. Chapman PB, Hauschild A, Robert C, et al., and BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
12. Nadler E, Broderick WC, Zarotsky V, Kim J. How do medical and pharmacy directors perceive the value of new cancer drugs? Drug Benefit Trends. 2009;21:120-30.
13. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
14. Yervoy (ipilimumab) prescribing Information. Bristol-Myers Squibb Co. Revised December 2013. Available at: http://packageinserts.bms.com/pi/ pi_yervoy.pdf. Accessed January 29, 2014.
15. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601-13.
16. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24(8):2174-80.
17. Eggermont AM. Can immuno-oncology offer a truly pan-tumour approach to therapy? Ann Oncol. 2012;23(Suppl 8):viii53-57.
18. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-47.
19. Lebbe C, Weber JS, Maio M, et al. Five-year survival rates for patients with metastatic melanoma treated with ipilimumab in phase II trials. Ann Oncol. 2012;23(Suppl 9):1116PD. [Abstract]
20. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.
21. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-97.
22. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
23. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAF V600E-mutated melanoma. J Clin Oncol. 2012;30(Suppl 15):8502. [Abstract]
24. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013;49(6):1297-304.
25. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011;82(3):201-09.
26. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767-74.
27. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703.
28. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 doseescalation trial. Lancet Oncol. 2012;13(8):782-89.
29. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
30. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482-89.
31. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251-55.
32. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-901.
33. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Melanoma Res. 2011;24:1020. [Abstract LBA1-1].
34. Klinac D, Gray ES, Millward M, Ziman M. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54.
35. Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013;73(11):1245-54.
36. Flaherty KT, Robert C, Hersey P, et al., for the METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-14.
37. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-97.
38. Yervoy (ipilimumab): serious and fatal immune-mediated adverse reactions. Risk evaluation and mitigation strategy. Bristol-Myers Squibb. 2012. Available at: http://www.yervoy.com/hcp/rems.aspx. Accessed January 29, 2014.
39. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, for the MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675-82.
40. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Paper presented at: 2013 European Society for Medical Oncology; September 27-October 1, 2013; Amsterdam, Netherlands. Abstract LBA24.
41. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365-66.
42. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773-81.
43. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, for the MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232-39.
44. National Comprehensive Cancer Network website. NCCN Clinical Practice Guidelines in Oncology. Melanoma v2.2014. Available at: http:// www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed February 2, 2014.
45. Swetter SM, Boldrick JC, Jung SY, Egbert BM, Harvell JD. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol. 2005;125(4):685-91.
46. Tas F, Keskin S, Karadeniz A, et al. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology. 2011;81(5-6):353-58.
47. Khan SA, Callahan M, Postow MA, et al. Ipilimumab in the treatment of uveal melanoma: the Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol. 2012;30(Suppl 15):8549. [Abstract]
48. Khattak M, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013;23(1):79-81.
49. Lawrence D, McDermott D, Hamid O, et al. Treatment of patients with stage III or IV melanoma on an ipilimumab expanded access program (EAP): results for 3 mg/kg cohort. Presented at: Society for Melanoma Research 2012 Congress; November 8-11, 2012; Hollywood, CA.
50. Maio M, Bondarenko I, Robert C, et al. Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine in phase 3 study CA184-024. Ann Oncol. 2012;23(Suppl 9):367. [Abstract]
51. Del Vecchio M, Simeone E, Chiarion Sileni V, et al. Efficacy and safety of ipilimumab in patients with pretreated, mucosal melanoma: experience from Italian clinics participating in the European Expanded Access Programme (EAP). Ann Oncol. 2012;23(Suppl 9):1130P. [Abstract]
52. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS. 2011;8(1):4.
53. Lebbé C, McDermott DF, Robert C, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial. Ann Oncol. 2010;21(Suppl 8):13240. [Abstract]
54. Queirolo P, Simeone E, De Galitiis F, et al. Efficacy and safety data from patients with advanced melanoma and brain metastases participating in the European ipilimumab expanded access programme (EAP) in Italy. Poster presented at: European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria.
55. Eigentler TK, Figl A, Krex D, et al., on behalf of the Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697-703.
56. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vermurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011;29(Suppl 15):8548. [Abstract]
57. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28(Suppl 15):8503. [Abstract]
58. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Poster presented at: European Society for Medical Oncology Congress; October 8-12, 2010; Milan, Italy. [Abstract LBA227]
59. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23.
60. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-109.
61. Harding JJ, Catalanotti F, Yaqubie A, et al. Vemurafenib in patients with BRAF-mutant melanoma with brain metastases. J Clin Oncol. 2013;31(Suppl 15):9060. [Abstract]
62. Dummer R, Goldinger SM, Turtschi CP, et al. Open-label pilot study of vemurafenib in previously treated metastatic melanoma (mM) patients (pts) with symptomatic brain metastases (BM). Poster presented at: European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria.
63. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95(24):1878-90.
64. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 2005;58(6):640-44.
65. Rimoldi D, Salvi S, Liénar D, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003;63(18):5712-15.
66. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-14.
67. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012;10:107.
68. Ascierto PA, Simeone E, Grimaldi AM, et al. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med. 2013;11:61.
69. Jang S, Atkins MB. Which drug, and when, for patients with BRAFmutant melanoma? Lancet Oncol. 2013;14(2):e60-69.
70. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
71. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
72. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33.
73. Hodi FS, Lee SJ, McDermott DF, et al., and Eastern Cooperative Oncology Group. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (ipi) versus ipi alone in metastatic melanoma: E1608. J Clin Oncol. 2013;31(Suppl 15):CRA9007. [Abstract]
74. Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31(Suppl 15):LBA9008. [Abstract]
75. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-40.
76. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287-97.
77. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-46.
78. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
79. Carvajal RD, Sosman JA, Quevedo F, et al. Phase II study of selumetinib versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol. 2013;31(Suppl 15):CRA9003. [Abstract]
80. Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness study. J Med Econ. 2013;16(2):202-12.